An Open-Label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2015
At a glance
- Drugs IMC EB10 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 24 Feb 2012 Actual patient number (26) added as reported by ClinicalTrials.gov.
- 08 Feb 2011 Actual End Date (1 Jan 2011) added as reported by ClinicalTrials.gov.